Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2500
Single User License Price INR 172500
Corporate User License Price USD 7500
Corporate User License Price INR 517500
Site License Price USD 5000
Site License Price INR 345000
Request a Quote

Report Title

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Quote Request for License Type
License Type Price  
Single User License USD 2500
Site License USD 5000
Enterprise Wide License USD 7500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents


Quote Request for License Type
License Type Price  
Single User License USD 2500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents



Executive Summary

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Summary

This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.

Questions topics-

- Further Phase I data required for Roche's capsid inhibitor RO7049389

- Replicor's US trial plans and transition from IV to subcutaneous REP 2139

- Efficacy of Spring Bank's inarigivir at 100mg in the Phase II ACHIEVE trial

- Expected role for inarigivir in HBV

- Efficacy of Arbutus's Q2W IV ARB-1467

- ARB-1467, TDF + Peg-IFN trial design, potential for functional cure, & regimen acceptability

- Future development of Arbutus's next-generation RNAi therapeutic AB-729For internal use only

Key Highlights

- Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ-6379 & ABI-H0731, with most concluding that Phase I data is insufficien

- KOLs agree Replicor is making positive steps towards REP 2139's development, but similar efficacy & safety must be demonstrated in the US trials and for the SC formulation

- Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our HBV key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Sept 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "recent & upcoming data for key HBV pipeline agents"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of HBV

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Roche

Replicor

Spring Bank

Arbutus

HBV, capsid inhibitor, functional cure, inarigivir


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person